Translational Development Acquisition Corp. (TDACU) Common Equity (2023 - 2026)
Translational Development Acquisition's (TDACU) quarterly Common Equity came in at -$6.8 million in Q1 2026, down 14.77% YoY from -$8.0 million in Q1 2025, and down 4.3% on a QoQ basis from -$6.5 million in Q4 2025.
Translational Development Acquisition Corp. (TDACU) Common Equity (2023 - 2026) Analysis & Trends
Translational Development Acquisition (TDACU) has 4 years of Common Equity data on file, last reported at -$6.8 million in Q1 2026.
- Quarterly Common Equity fell 14.77% year-over-year to -$6.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$6.8 million (down 14.77% YoY) and the FY2025 annual result came in at -$6.5 million, down 16.87% from the prior year.
- Common Equity fell to -$6.8 million in Q1 2026, from -$6.5 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of -$507658.0 in Q4 2023 to a low of -$6.8 million in Q1 2026.
- A 4-year average of -$4.8 million and a median of -$6.1 million in 2025 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2025 — Common Equity sank 1018.03% — and 2026, when it dropped 14.77%.
- Tracing TDACU's Common Equity over 4 years: stood at -$507658.0 in 2023, then slumped by 1002.63% to -$5.6 million in 2024, then retreated by 16.87% to -$6.5 million in 2025, then declined by 4.3% to -$6.8 million in 2026.
- The last three Common Equity figures came in at -$6.8 million (Q1 2026), -$6.5 million (Q4 2025), and -$6.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.82 Mn |
| Dec 31, 2025 | -6.54 Mn |
| Sep 30, 2025 | -6.38 Mn |
| Jun 30, 2025 | -6.17 Mn |
| Mar 31, 2025 | -5.94 Mn |
| Dec 31, 2024 | -5.60 Mn |
| Sep 30, 2024 | -570,626.00 |
| Dec 31, 2023 | -507,658.00 |